AU2008209320B2 - Insulin sensitisers and methods of treatment - Google Patents

Insulin sensitisers and methods of treatment Download PDF

Info

Publication number
AU2008209320B2
AU2008209320B2 AU2008209320A AU2008209320A AU2008209320B2 AU 2008209320 B2 AU2008209320 B2 AU 2008209320B2 AU 2008209320 A AU2008209320 A AU 2008209320A AU 2008209320 A AU2008209320 A AU 2008209320A AU 2008209320 B2 AU2008209320 B2 AU 2008209320B2
Authority
AU
Australia
Prior art keywords
alkyl
alkoxy
methazolamide
phenyl
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008209320A
Other languages
English (en)
Other versions
AU2008209320A1 (en
Inventor
James Alexander Campbell
Gregory Royce Collier
Nicky Konstantopoulos
Guy Yeoman Krippner
Juan-Carlos Molero-Navajas
Kenneth Russell Walder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naia Metabolic Inc
Original Assignee
Naia Metabolic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007902013A external-priority patent/AU2007902013A0/en
Application filed by Naia Metabolic Inc filed Critical Naia Metabolic Inc
Priority to AU2008209320A priority Critical patent/AU2008209320B2/en
Publication of AU2008209320A1 publication Critical patent/AU2008209320A1/en
Application granted granted Critical
Publication of AU2008209320B2 publication Critical patent/AU2008209320B2/en
Assigned to NAIA Metabolic, Inc. reassignment NAIA Metabolic, Inc. Request for Assignment Assignors: VERVA PHARMACEUTICALS LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2008209320A 2007-01-25 2008-01-25 Insulin sensitisers and methods of treatment Ceased AU2008209320B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008209320A AU2008209320B2 (en) 2007-01-25 2008-01-25 Insulin sensitisers and methods of treatment

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US89776907P 2007-01-25 2007-01-25
US60/897,769 2007-01-25
AU2007902013A AU2007902013A0 (en) 2007-04-17 Inhibitory compounds
AU2007902013 2007-04-17
US98433507P 2007-10-31 2007-10-31
US60/984,335 2007-10-31
US737607P 2007-12-11 2007-12-11
US61/007,376 2007-12-11
AU2008209320A AU2008209320B2 (en) 2007-01-25 2008-01-25 Insulin sensitisers and methods of treatment
PCT/AU2008/000089 WO2008089521A1 (en) 2007-01-25 2008-01-25 Insulin sensitisers and methods of treatment

Publications (2)

Publication Number Publication Date
AU2008209320A1 AU2008209320A1 (en) 2008-07-31
AU2008209320B2 true AU2008209320B2 (en) 2013-05-30

Family

ID=39644028

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008209320A Ceased AU2008209320B2 (en) 2007-01-25 2008-01-25 Insulin sensitisers and methods of treatment

Country Status (12)

Country Link
US (3) US8455432B2 (enExample)
EP (1) EP2106260B8 (enExample)
JP (1) JP5301465B2 (enExample)
CN (1) CN101801375B (enExample)
AU (1) AU2008209320B2 (enExample)
CA (1) CA2676051C (enExample)
ES (1) ES2660170T3 (enExample)
NO (1) NO2106260T3 (enExample)
NZ (1) NZ579229A (enExample)
PL (1) PL2106260T3 (enExample)
PT (1) PT2106260T (enExample)
WO (1) WO2008089521A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
US20200155558A1 (en) * 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ702666A (en) * 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction
BR112014029308A2 (pt) * 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática
AU2013202988B2 (en) * 2012-06-29 2016-04-21 NAIA Metabolic, Inc. Method of improving liver function
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013800A2 (en) * 2000-08-11 2002-02-21 Einar Stefansson Method for the prevention and treatment of retinopathy

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2994701A (en) 1961-08-01 Z-sulfamyr
US2783241A (en) 1957-02-26 S-acylimino-x-substituted-az-i
US2554816A (en) 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
GB795174A (en) 1954-10-13 1958-05-21 Upjohn Co Heterocyclic sulphonamides
US2835702A (en) 1956-05-02 1958-05-20 Merck & Co Inc Benzene 1, 3 disulfonamides possessing diuretic properties
US2978457A (en) 1959-04-06 1961-04-04 Merck & Co Inc 5-acylamido-4-substituted-thiazole-2-sulfonamides having diuretic properties
US3157572A (en) 1961-01-06 1964-11-17 American Cyanamid Co Parenteral diuretic compositions of 5-acylimino-4-substituted-delta2-1, 3, 4-thiadiazolidine-2-sulfonamides
US3668248A (en) 1964-09-30 1972-06-06 Lilly Co Eli 5-chloro-2,4-bis(sulfamoyl)fluorobenzene and 5-chloro-2,4-bis(chlorosulfonyl)fluorobenzene
FR2468366A1 (fr) 1979-10-31 1981-05-08 Stoclet Alain Medicament antiglaucomateux a base d'acetazolamide ou de methazolamide
DE3377130D1 (en) 1982-05-28 1988-07-28 Ciba Geigy Ag Sulfonyl(thio)ureas, process for their preparation and their use as herbicides and/or growth regulating agents
IT1224860B (it) 1988-07-29 1990-10-24 Istituto Chimico Internazional Composti correlati all'acetozolammi de con attivita' inibitrice dell'anidrasi carbonica, utili in particolare nel trattamento del glaucoma
GB2223166B (en) 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US4990523A (en) 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5585377A (en) 1990-04-09 1996-12-17 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5225424A (en) 1992-10-21 1993-07-06 University Of Iowa Research Foundation Methazolamide-derived carbonic anhydrase inhibitors
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP0869785B1 (en) 1995-11-17 2002-08-28 PHARMACIA & UPJOHN COMPANY 4-hydroxycoumarin-3-carboxamides for the treatment of non-insulin dependent diabetes mellitus
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
AU2382601A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel method of treatment
CA2415093A1 (en) 2000-07-07 2002-01-17 Carlos Plata-Salaman Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
FR2816841B1 (fr) 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
US6800669B2 (en) 2000-12-22 2004-10-05 Dow Global Technologies Inc. Propylene copolymer foams
EP1695716A2 (en) 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
CA2364985A1 (en) 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
CA2516142A1 (en) 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
ES2385219T3 (es) * 2003-09-12 2012-07-19 Merck Serono Sa Derivados de sulfonamida para el tratamiento de diabetes
TW200533336A (en) 2004-03-02 2005-10-16 Fujisawa Pharmaceutical Co Concomitant drugs
RU2395503C2 (ru) 2004-05-19 2010-07-27 Зольвай Фармасьютиклз Гмбх Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US20070110707A1 (en) * 2005-11-04 2007-05-17 Washington University Method of treating diseases involving non-enzymatic glycation
US7670794B2 (en) 2005-11-04 2010-03-02 Washington University Managing glycemia status in diabetic patients
TW200804393A (en) 2005-11-14 2008-01-16 Solvay Pharm Gmbh Novel N-sulfamoyl-N'-benzopyranpiperidines for medical use
JP2009515928A (ja) 2005-11-14 2009-04-16 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング カルボニックアンヒドラーゼの阻害剤としてのｎ−スルファモイル−ｎ’−ベンゾピランピペリジン
WO2007065948A1 (en) * 2005-12-09 2007-06-14 Solvay Pharmaceuticals Gmbh Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
WO2007114948A2 (en) 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
TW201105338A (en) 2009-07-01 2011-02-16 Kissei Pharmaceutical Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor
CN103068400A (zh) 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
JP5722892B2 (ja) 2010-07-15 2015-05-27 武田薬品工業株式会社 複素環化合物
BR112014029308A2 (pt) 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática
NZ702666A (en) 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013800A2 (en) * 2000-08-11 2002-02-21 Einar Stefansson Method for the prevention and treatment of retinopathy

Also Published As

Publication number Publication date
US10172837B2 (en) 2019-01-08
US20140011848A1 (en) 2014-01-09
US20110003740A1 (en) 2011-01-06
CA2676051C (en) 2017-06-06
US9452148B2 (en) 2016-09-27
CA2676051A1 (en) 2008-07-31
EP2106260B1 (en) 2017-12-06
EP2106260B8 (en) 2018-04-04
EP2106260A4 (en) 2010-05-26
NO2106260T3 (enExample) 2018-05-05
EP2106260A1 (en) 2009-10-07
CN101801375A (zh) 2010-08-11
JP5301465B2 (ja) 2013-09-25
ES2660170T3 (es) 2018-03-21
NZ579229A (en) 2011-07-29
CN101801375B (zh) 2014-01-01
WO2008089521A1 (en) 2008-07-31
PL2106260T3 (pl) 2018-06-29
US20170079960A1 (en) 2017-03-23
US8455432B2 (en) 2013-06-04
AU2008209320A1 (en) 2008-07-31
JP2010516711A (ja) 2010-05-20
PT2106260T (pt) 2018-03-05

Similar Documents

Publication Publication Date Title
US10172837B2 (en) Insulin sensitisers and methods of treatment
CN100383132C (zh) 用作代谢调节剂的为丙二酸单酰辅酶a脱羧酶抑制剂的吡咯
TWI286476B (en) Combination of cytochrome P450 dependent protease inhibitors
EP2394647A1 (en) Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
ZA200401846B (en) Ihibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma.
HUE029479T2 (en) Preparations and methods for treating diabetes and neuropsychological disorder
Hallaj et al. Systemic carbonic anhydrase inhibitors in common ophthalmic diseases: A Scoping review from a clinical standpoint
US6399658B1 (en) Composition containing ascorbic acid
JP3585045B2 (ja) ミトコンドリア疾病の処置におけるリルゾールの適用
DE69931814T2 (de) Umwandlung von cox-inhibierenden, nicht cox-2 selektiven inhibitoren in derivate von cox-2 selektiven inhibitoren
US12414927B2 (en) CXCR5 antagonists and methods of treating diseases or disorders using same
US20110118317A1 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
AU2003293937A1 (en) Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
US20180333398A1 (en) Method of weight reduction
HK1132198B (en) Insulin sensitisers and methods of treatment
HK1132198A (en) Insulin sensitisers and methods of treatment
CA2401016A1 (en) Scytonemin and methods of using thereof
JP7280470B2 (ja) 特定アミノ酸またはアミノ酸様物質による低酸素応答制御
WO2006085686A1 (ja) 神経因性疼痛治療剤
BR112019021140A2 (pt) composição, método para reduzir os níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento, método de indução do bege de adipócitos ou prevenção da degeneração das células beta do pâncreas, e, ativador de lyn cinase e agonista de trpm8 para uso na redução dos níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento.
WO2004028537A1 (en) Use of thiazolidinedione derivatives as aldose reductase inhibitors
KR20170133293A (ko) ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 25 JAN 2016 TO 25 FEB 2017 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 25 FEB 2017

PC Assignment registered

Owner name: NAIA METABOLIC, INC.

Free format text: FORMER OWNER(S): VERVA PHARMACEUTICALS LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired